TICKERNERD
Menu
NUWENUWEHealthcare · Medical Devices

NUWE Stock Forecast: Nuwellis, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.61
−7.47% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$160,429.00
Ticker Nerd rank
24 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−19.1%
1M
−48.9%
YTD
−97.4%
1Y
−99.5%
From 52W high
−99.3%
From 52W low
0.0%
$2
$231
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NUWE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Accruals
90
Issuance
41
Growth
37
Quality
33
Revisions
25
Momentum
24
Volatility
7
Value
0

Size (100): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership.

Wall Street

NUWE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200$250Oct 25Jan 26Apr 26Jul 26NUWE

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2024Roth MKMReiteratesBuy$17
29 July 2024Roth MKMInitiatesBuy—
8 Nov 2023Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NUWE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Nuwellis, Inc. (NUWE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 73% of US stocks

Price / sales
0.0×

Cheaper than 99% of US stocks

Price / book
0.0×

Cheaper than 91% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
26.2%

Higher than 77% of US stocks

Earnings growth (YoY)
26.2%

Higher than 66% of US stocks

Gross margin
70.1%

Higher than 83% of US stocks

Operating margin
−190.1%

Higher than 11% of US stocks

Net margin
−217.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−609.4%

Higher than 2% of US stocks

Return on assets
−112.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NUWE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NUWENuwellis, Inc.$160,429.00
24
PFSAProfusa, Inc.$561,800.00
8
BJDXBluejay Diagnostics, Inc.$889,900.00
21
VTAKCatheter Precision, Inc.$906,000.00
28
AEMDAethlon Medical, Inc.$1.7M
23
IVFINVO Fertility, Inc.$2.1M
47
FEEDENvue Medical, Inc.$2.9M
25
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NUWE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NUWE news & analysis

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewsWire · 31 July 2026neutral

Nuwellis announced the pricing of a $3.4 million registered direct offering conducted at-the-market under Nasdaq rules, and separately received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.

Why it matters — A NUWE watcher would care because the new offering and warrant exercises indicate changes in the company's capital structure and near-term cash position.

Nuwellis Stock Explodes Thursday: What's Driving the Action?

Benzinga · 30 July 2026positive

Nuwellis shares surged Thursday afternoon as traders reacted to new pediatric data linked to the company's Aquadex ultrafiltration therapy.

Why it matters — A NUWE watcher would care because the positive market reaction reflects investor optimism around the potential of the Aquadex pediatric data to expand the therapy's adoption and commercial prospects.

Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy

GlobeNewsWire · 30 July 2026positive

Nuwellis announced the acceptance of a new single-center retrospective study by Frontiers in Pediatrics. The peer-reviewed research supports an alternative anticoagulation strategy using epoprostenol for Aquadex ultrafiltration therapy in critically ill pediatric patients.

Why it matters — This publication adds independent, peer-reviewed clinical evidence for Nuwellis' Aquadex technology, potentially supporting broader adoption in pediatric critical care.

Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin

GlobeNewsWire · 28 July 2026positive

Nuwellis has expanded into Wisconsin by installing its first Aquadex SmartFlow® systems at a leading pediatric healthcare institution, further growing the company's presence in pediatric critical care.

Why it matters — This expansion signals Nuwellis's continued penetration of the pediatric critical care market with its Aquadex SmartFlow technology, broadening its geographic footprint at a premier academic medical center.

Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth

GlobeNewsWire · 27 July 2026positive

Nuwellis announced preliminary unaudited revenue results for the second quarter of 2026, showing year-over-year growth of 14% for the quarter and 20% for the first half of the year. The company cited continued commercial momentum from its Aquadex Ultrafiltration platform and plans to report full quarterly financial results on August 13.

Why it matters — NUWE watchers would note that the preliminary double-digit revenue growth signals continued commercial adoption of the company's core Aquadex platform ahead of the formal earnings release.

FAQ

Frequently asked questions about NUWE stock

Is NUWE stock a buy right now?

Of the 1 analysts covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 24 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NUWE?

As at 1 Aug 2026, Nuwellis, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the NUWE stock forecast for 2030?

No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.

How has NUWE stock performed over the past year?

Nuwellis, Inc. returned -99.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuwellis, Inc. do?

Nuwellis Inc. is a medical technology company that develops, manufactures, and commercializes medical devices for ultrafiltration therapy to manage fluid overload in patients with cardiorenal conditions.

What is the latest news on NUWE?

The most recent item we track (GlobeNewsWire, 31 July 2026): "Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules". Nuwellis announced the pricing of a $3.4 million registered direct offering conducted at-the-market under Nasdaq rules, and separately received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.

Company

About Nuwellis, Inc.

Nuwellis Inc. is a medical technology company that develops, manufactures, and commercializes medical devices for ultrafiltration therapy to manage fluid overload in patients with cardiorenal conditions. Its primary products include the Aquadex FlexFlow and Aquadex SmartFlow systems, which provide clinicians with precise, safe methods to remove excess salt and water from patients whose conditions are unresponsive to diuretics, particularly those suffering from heart failure, critical care challenges, and pediatric cases. The Aquadex systems consist of a console with electromechanical pumps and display screen, disposable blood circuit sets with tubing, filters, sensors, and connectors, and disposable catheters. These devices support both temporary and extended use in adult and pediatric patients weighing 20 kilograms or more. Nuwellis Inc. markets its products to hospitals and clinics through a direct salesforce in the United States and independent specialty distributors in select international markets. The company also advances pediatric innovations like the Vivian pediatric system, focusing on safer fluid management in complex clinical scenarios. Founded in 1999 and headquartered in Eden Prairie, Minnesota, Nuwellis Inc. plays a key role in enhancing cardiorenal care by centralizing fluid management in treatment protocols.

CEO Mr. John L. Erb · 38 employees · United States · https://www.nuwellis.com